Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1997-02-04
1999-01-26
Grumbling, Matthew V.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
544345, A61K 31495, C07D40312
Patent
active
058639160
ABSTRACT:
Disclosed are compounds of the formula: ##STR1## or pharmaceutically acceptable salts thereof; wherein n is zero or 1; R.sup.4, R.sup.5, R.sup.6 are independently hydrogen, nitro, amino, halo, haloalkyl, cyano, alkyl, cycloalkyl, alkenyl, alkynyl, azido, acylamino, alkylsulfonyl, aryl, substituted aryl, heteroaryl, alkoxy, trialkylsilyl-substituted alkoxy, aryloxy, substituted aryloxy, heteroaryloxy, a heterocyclic group, a heterocyclicoxy group, aralkoxy, or haloalkoxy; and R.sup.c and R.sup.d are defined in the specification. These compounds have high binding to the glycine site of the NMDA receptor. Also disclosed are methods of treating pathophysiologic conditions associated with neuronal degeneration, convulsions, anxiety, chronic pain, pyschosis, opiate tolerance, and inducing anesthesia.
REFERENCES:
patent: 4296114 (1981-10-01), Appleton et al.
patent: 5055465 (1991-10-01), Davey
patent: 5283244 (1994-02-01), Sakamoto et al.
patent: 5424311 (1995-06-01), Billhardt-Troughton et al.
Winterfeld, Chemical Abstracts 72:78970 (1970), see especially RN 25710-21-8.
Albert, A. et al., "Pteridine studies. VIII. Degradation of pteridine. Methylation of the hydroxypteridines and degradation of the products," Chem. Abs. 51:1977b (1957).
Albert, A. et al., "Pteridine studies. X. Pteridines with more than one hydroxy or amino group," Chem. Abs. 51:6654c (1957).
Albert, A. et al., "Pteridine Studies. Part XXXV. The Structure of the Hydrated Dimer Formed by the Action of Dilute Acid on 4-Methylpteridine," J. Chem. Soc. (C):1181-1187 (1968).
Bigge, C. F. and P. A. Boxer, "Chapter 2. Neuronal Cell Death and Strategies for Neuroprotection," Ann. Rep. Med. Chem. 29:13-22 (Aug. 1994).
Boast, C. A. et al., "The N-methyl-D-aspartate antagonists CGS 19755 and CPP reduce ischemic brain damage in gerbils," Brain Res. 442:345-348 (1988). pyrazines et synthese de la dioxo-1.4 tetrahydro-1.2.3.4 273:1645-1648 (1971).
Brady, K. T. et al., "Stereoisomers of N-Allylnormetazocine: Phencyclidine-Like Behavioral Effects in Squirrel Monkeys and Rats," Science, 215:178-180 (1982).
Burton, D. E. et al., "Halogeno-o-phenylenediamines and Derived Heterocycles. Part I. Reductive Fission of Benzotriazoles to o-Phenylenediamines," J. Chem. Soc. (C):1268-1280 (1968).
Choi, D. W. et al., "Glutamate Neurotoxicity in Cortical Cell Culture," J. Neurosci. 7(2):357-368 (1987).
Church, J. et al., "Ketamine and MK-801 as Neuroprotective Agents in Cerebral Ischemia/Hypoxia," in: Sigma and Phencyclidine-Like Compounds as Molecular Probes in Biology, Domino, E. F. and J.-M. Kamenka, eds., NPP Books: Ann Arbor (1988).
Clark, J. et al., "Heterocyclic Studies. Part VIII. 2-Phenylpteridine and Some Related Compounds," J. Chem. Soc. (C):1408-1412 (1969).
Claek, J. et al., "Heterocyclic Studies. Part X. 4-Phenylpteridine and Some Methyl Derivatives," J. Chem. Soc. (C):1883-1886 (1969).
Collins, R. C., "Selective Vulnerability of Brain: New Insights from the Excitatory Synapse," Metabolic Brain Dis. 1(4):231-240 (1986).
Collins, R. C. et al., "Selective Vulnerability of the Brain: New Insights into the Pathophysiology of Stroke," Ann. Internal Med. 110(12):992-1000 (1989).
Daines, R. A. et al., "Trisubstituted Pyridine Leukotriene B.sub.4 Receptor Antagonists: Synthesis and Structure-Activity Relationships," J. Med. Chem. 36:3321-3332 (Nov. 1993).
Decker, T. and M.-L. Lohmann-Matthes, "A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity," J. Imm. Meth. 15:61-69 (1988).
Dickenson, A. H. and E. Aydar, "Antagonism at the Glycine site on the NMDA receptor reduces spinal nociception in the rat," Neruosci. Lett. 121:263-266 (1991).
Dubuisson, D. and S. G. Dennis, "The Formalin Test: A Quantitative Study of the Analgesic Effects of Morphine, Meperidine, and Brain Stem Stimulation in Rats and Cats," Pain 4:161-174 (1977).
Fletcher, E. J. and D. Lodge, "Glycine reverses antagonism of N-methyl-D-aspartate (NMDA) by 1-hydroxy-3-aminopyrrolidone-2 (HA-966) but not by D-2-amino-5-phophonovalerate (D-AP5) on rat cortical slices," Eur. J. Pharmcol. 151:161-162 (1988).
Fletcher, E. J. et al., "Involvement of Glycine in Excitatory Neurotransmission," in: Glycine Neurotransmission, Ottersen, O. P. and J. Storm-Mathisen, eds., John Wiley & Sons Ltd. (1990).
Gill, R. et al., "Systemic Administration of MK-801 Protects Against Ischemia-Induced Hippocampal Neurodegeneration in the Gerbil," J. Neurosci. 7(10):3343-3349 (1987).
Globus, M. Y.-T. et al., "Comparative Effect of Transient Global Ischemia on Extracellular Levels of Glutamate, Glycine, and .gamma.-Aminobutyric Acid in Vulnerable and Nonvulnerable Brain Regions in the Rat," J. Neurochem. 57(2):470-478 (1991).
Gottlieb, R. and W. Pfleiderer, "Synthese und elektrochemisches Verhalten von 6,7-Dioxo-tetrahydropteridinen und 2,3-Dioxotetrahydropyrido-pyrazinen," Chem. Ber.111:1763-1779 (1978).
Gray, N. M. et al., "Novel Indole-2-carboxylates as Ligands for the Strychnine-Insensitive N-Methyl-D-aspartate-Linked Glycine Receptor," J. Med. Chem. 34:1283-1292 (1991).
Haley, J. E. et al., "Evidence for spinal N-methyl-D-aspartate receptor involvement in prolonged chemical nociception in the rat," Brain Res. 518:218-226 (1990).
Huettner, J. E. and B. P. Bean, "Block of N-methyl-D-aspartate-activated current by the anticonvulsant MK-801: Selective binding to open channels," Proc. Natl. Acad. Sci. USA 85:1307-1311 (1988).
Huidobro, F. et al., "Studies on Tolerance Development to Single Doses of Morphine in Mice," J. Pharmacol. Exp. Ther. 198(2):318-329 (1976).
Hunger, A. et al., "1-Aminoalkyl-7-azabenzimidazoles," Chem. Abstr. 63:14876 (1965).
Israel, M. and A. R. Day, "Preparation of Pyrido-(2,3)-pyrazines, Pyrido-(3,4) pyrazines and Imidazo-(b)-pyridines," J. Org Chem. 24:1455-1460 (1959).
Johnson, J. W. and P. Ascher, "Glycine potentiates the NMDA response in cultured mouse brain neurons," Nature 325:529-531 (1987).
Jones, B. J. et al., "The potential anxiolytic activity of GR38032F, a 5-HT.sub.3 -receptor antagonist," Br. J. Pharmacol. 93:985-993 (1988).
Kaye, I. A., "Some Substituted Pyrido(2,3)pyrazines," J. Med. Chem. 7(2):240-241 (1964).
Keana, J. F. W. et al., "Synthesis and characterization of a series of diaryguanidines that are noncompetitive N-methyl-D-aspartate receptor antagonists with neuroprotective properties," Proc. Natl. Acad. Sci. USA 86:5631-5635 (1989).
Kemp, J. A. et al., "7-Chlorokynurenic acid is a selective antagonist at the glycine modulatory site of the N-methyl-D-aspartate receptor complex," Proc. Natl. Acad. Sci. USA 85:6547-6550 (1988).
Kessler, M. et al., "A Glycine Site Associated with N-Methyl-D-Aspartic Acid Receptors: Characterization and Identification of a New Class of Antagonists," J. Neurochem. 52(4):1319-1328 (1989).
Koek, W. et al., "MK-801, a Proposed Noncompetitive Antagonist of Excitatory Amino Acid Nuerotransmission, Produces Phencyclidine-Like Behavioral Effects in Pigeons, Rats and Rhesus Monkeys," J. Pharmacol. Exp. Ther. 245(3):969-974 (1988).
Kornetsky, C. and G. Bain, "Morphine: Single-Dose Tolerance," Science 162:1011-1012 (1968).
Kress, T. J. et al., "Selective Chlorinations in Sulfuric Acid, Synthesis of Some 2-Amino-5-chloro-, 2-Amino-3-chloro-and 2-Amino-3,5-dichloropyridines," J. Org. Chem. 41(1):93-96 (1976).
Kulagowski, J. J. et al., "3'-(Arylmethyl)-and 3'-(Aryloxy)-3-phenyl-4-hydroxyquinolin-2(1H)-ones: Orally Active Antagonists of the Glycine Site on the NMDA Receptor," J. Med. Chem. 37:1402-1405 (May 1994).
Landon, R. M. and R. J. Robbins, "Somatostatin Release from Dissociated Cerebral Cortical Cell Cultures," Meth. Enzymol. 124:412-424 (1986).
Leeson, P. D., "Glycine-Site N-Methyl-D-Aspartate Receptor Antagonists," in: Drug Design for Neuroscience, Kozikowski, A. P., ed., Raven Press, Ltd.: New York, pp. 339-381 (Jul. 1993).
Leeson, P. D. and L. L. Iverson, "The Glycine Site on the NMDA Receptor: Structure-Activity Relationships and Therapeutic Potential," J. Med. Chem. 37(24):4053-4067 (Nov. 1994).
Leo, A. et al., "Partition Coeffic
Cai Sui Xiong
Keana John F. W.
Weber Eckard
Cocensys Inc.
Grumbling Matthew V.
State of Oregon acting by and through the Oregon State Board of
The Regents of the University of California
LandOfFree
8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1450631